InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,173.60
(
0.55%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.37%
)
Bitcoin
66,249.87
(
-0.76%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

bb56

Send PM Follow Ignore
Followers 0
Posts 9
Boards Moderated 0
Alias Born 06/30/2010

bb56

Re: None

Wednesday, 09/14/2011 7:50:45 AM

Wednesday, September 14, 2011 7:50:45 AM

Post# of 80490
theflyonthewall.com:
Ariad ponatinib opportunity may be underappreciated, says Oppenheimer. Oppenheimer believes that investors may be underappreciating the long-term opportunity for Ariad's ponatinib in 1st-line CML. The firm recommends buying the stock into interim PACE results at ASH in December, and the firm maintains an Outperform rating on the shares.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up